News

Tebentafusp Shows Long-Term Survival Benefit in Metastatic Uveal Melanoma, 5-Year Study Confirms

Treatment /

Five-year results from a phase 3 study show that tebentafusp-tebn significantly improves survival in patients with HLA-A*02:01–positive metastatic uveal melanoma. Patients treated with tebentafusp lived a median of 21.6 months, compared with 16.9 months for those receiving standard therapies such as pembrolizumab, ipilimumab, or dacarbazine. At five years, 16% of patients in the tebentafusp group were […]

Tebentafusp Shows Long-Term Survival Benefit in Metastatic Uveal Melanoma, 5-Year Study Confirms Read More »

China Approves Belantamab Combination, Showing Major Survival Gains in Multiple Myeloma

Drug Approvals /

National Medical Products Administration has approved belantamab mafodotin with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least one prior therapy. The approval is based on the DREAMM-7 trial, where the combination significantly outperformed a standard daratumumab-based regimen. It extended progression-free survival to 36.6 months versus 13.4 months and reduced

China Approves Belantamab Combination, Showing Major Survival Gains in Multiple Myeloma Read More »

HOXD13 Protein Found to Drive Melanoma Growth and Immune Evasion

Research Advances /

Researchers have identified a protein called HOXD13 as a key driver of melanoma. The study shows that HOXD13 helps cancer grow in two major ways. First, it promotes tumor growth by triggering angiogenesis, the process of forming new blood vessels. These vessels supply the tumor with oxygen and nutrients, allowing it to expand more quickly.

HOXD13 Protein Found to Drive Melanoma Growth and Immune Evasion Read More »

CAR T-Cell Therapy Ciltacabtagene Autoleucel Shows 100% Response in Early Multiple Myeloma Trial

Clinical Trails /

Results from the CAR-PRISM phase 2 trial show that the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) produced remarkable outcomes in patients with high-risk smoldering multiple myeloma, a precursor to active cancer. All 20 patients in the study responded to treatment, with most achieving deep remissions. Every patient became minimal residual disease (MRD) negative within two

CAR T-Cell Therapy Ciltacabtagene Autoleucel Shows 100% Response in Early Multiple Myeloma Trial Read More »

Genomic Profiling Plus ctDNA Testing Identifies Targeted Treatment Options for Most Breast and Colorectal Cancer Patients

Targeted Therapy /

New research shows that combining comprehensive tumor profiling with blood-based DNA monitoring can guide treatment for most patients with breast and colorectal cancer. Using advanced genomic testing alongside circulating tumor DNA (ctDNA) analysis, researchers found that 98% of patients had at least one actionable genetic alteration, and over half had markers linked to approved targeted

Genomic Profiling Plus ctDNA Testing Identifies Targeted Treatment Options for Most Breast and Colorectal Cancer Patients Read More »

FDA Approves Nivolumab Plus AVD as New First-Line Treatment for Advanced Hodgkin Lymphoma

Drug Approvals /

The U.S. FDA has approved nivolumab (Opdivo) in combination with AVD chemotherapy for patients aged 12 and older with newly diagnosed advanced classical Hodgkin lymphoma. This approval expands access to a modern immunotherapy-based treatment for both adults and adolescents. Results from the SWOG 1826 trial showed the combination reduced the risk of disease progression or

FDA Approves Nivolumab Plus AVD as New First-Line Treatment for Advanced Hodgkin Lymphoma Read More »

Stem Cell Transplant Relapse Remains Key Challenge, DLI Shows Promise in Early Intervention

Research Advances /

A study examined relapse in patients with myelofibrosis and blast-phase myeloproliferative neoplasms after allogeneic stem cell transplant. Among 47 patients treated between 2013 and 2024, 21% experienced recurrence, with 3- and 5-year relapse rates both at 35%. Molecular relapse typically appeared about six months after transplant and was often detected by declining donor chimerism. Donor

Stem Cell Transplant Relapse Remains Key Challenge, DLI Shows Promise in Early Intervention Read More »

New KRAS-Targeting Strategies Bring Fresh Hope to Cancer Treatment

Treatment /

Researchers are reporting major progress in targeting KRAS, a cancer-driving protein long considered “undruggable.” Mutations in KRAS keep cells stuck in a constant growth mode, contributing to some of the most aggressive cancers, including pancreatic cancer. Instead of simply trying to block KRAS activity, scientists are now developing “degrader” drugs that label the mutant protein

New KRAS-Targeting Strategies Bring Fresh Hope to Cancer Treatment Read More »

Experimental Drug Elraglusib Shows Significant Survival Gains in Metastatic Pancreatic Cancer Trial

Clinical Trails /

A phase 2 clinical trial of the experimental drug elraglusib has shown promising results for patients with metastatic pancreatic cancer, according to research published in Nature Medicine. Patients who received elraglusib along with chemotherapy were twice as likely to be alive after one year compared to those who received chemotherapy alone, with survival rates of

Experimental Drug Elraglusib Shows Significant Survival Gains in Metastatic Pancreatic Cancer Trial Read More »

Healthy Diets Linked to Unexpected Rise in Lung Cancer Among Young Non-Smokers

Research Advances /

A new study has found a surprising link between healthy diets and a higher risk of lung cancer in non-smokers under age 50, especially women. Researchers reported that younger non-smokers diagnosed with lung cancer had better diet quality than average, scoring 65 on the Healthy Eating Index compared to the national average of 57. Women in

Healthy Diets Linked to Unexpected Rise in Lung Cancer Among Young Non-Smokers Read More »